denkapparat is a private holding and investment firm founded by Berlin-based serial entrepreneurs Markus Hannebauer and Arno Schödl. We invest in software, real estate and biotechnology working with a network of handpicked partners. The core and main fund source of our portfolio is think-cell—the global leader in charting software for Microsoft PowerPoint.

think-cell is the leading productivity software when it comes to presenting data with charts. think-cell is used by 1m+ professionals at 25k+ companies, including consulting firms, investment banks and global corporations. After growing the completely bootstrapped company to an ARR of 100m+ EUR with just 50 employees, and after being think-cell's CEO for 20 years, I recently moved on to become Chairman and took the helm of the founders' family office denkapparat.

Unlike traditional antibiotics, our approach blocks the pathogenicity of bacteria without directly killing them. This pathoblocking prevents bacteria from harming their host. Disarmed and unable to infect human cells, the bacteria are removed from the body.

We have developed a targeted therapy designed to effectively modulate immune responses. This breakthrough not only has the potential to significantly reduce the risk of complications like GVHD, but also offers promise in treating a wide range of autoimmune and inflammatory diseases.

C1 develops new, climate-friendly chemical production processes by rethinking chemical reactions from the atomic level all the way up to production scale.

Every person with a chronic illness should receive the best possible care. That's why we at Vantis focus on holistic solutions that simply work for patients. On-site at the doctor's office as well as digitally at home.